

# Shu-Fu Lin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1858112/publications.pdf>

Version: 2024-02-01

31  
papers

759  
citations

516561

16  
h-index

526166

27  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1079  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel Oncolytic Agent GLV-1h68 Is Effective Against Malignant Pleural Mesothelioma. <i>Human Gene Therapy</i> , 2008, 19, 774-782.	1.4	67
2	Synergy of a Herpes Oncolytic Virus and Paclitaxel for Anaplastic Thyroid Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 1519-1528.	3.2	57
3	Oncolytic Vaccinia Virotherapy of Anaplastic Thyroid Cancer <i>in Vivo</i> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4403-4407.	1.8	54
4	Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. <i>Surgery</i> , 2007, 142, 976-983.	1.0	46
5	Prognosis of Multifocal Papillary Thyroid Carcinoma. <i>International Journal of Endocrinology</i> , 2013, 2013, 1-6.	0.6	45
6	Drug combination in vivo using combination index method: Taxotere and T607 against colon carcinoma HCT-116 xenograft tumor in nude mice. <i>Synergy</i> , 2016, 3, 15-30.	1.1	45
7	Nationwide cohort study on the epidemiology and survival outcomes of thyroid cancer. <i>Oncotarget</i> , 2017, 8, 78429-78451.	0.8	45
8	Nectin-1 Is a Marker of Thyroid Cancer Sensitivity to Herpes Oncolytic Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1965-1970.	1.8	42
9	Utility of a PI3K/mTOR Inhibitor (NVP-BE2235) for Thyroid Cancer Therapy. <i>PLoS ONE</i> , 2012, 7, e46726.	1.1	38
10	A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer. <i>PLoS ONE</i> , 2017, 12, e0172315.	1.1	36
11	Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment. <i>PLoS ONE</i> , 2013, 8, e77684.	1.1	35
12	Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models. <i>Oncotarget</i> , 2017, 8, 41294-41304.	0.8	33
13	MART-10, the vitamin D analog, is a potent drug to inhibit anaplastic thyroid cancer cell metastatic potential. <i>Cancer Letters</i> , 2015, 369, 76-85.	3.2	29
14	1H Nuclear Magnetic Resonance (NMR)-Based Cerebrospinal Fluid and Plasma Metabolomic Analysis in Type 2 Diabetic Patients and Risk Prediction for Diabetic Microangiopathy. <i>Journal of Clinical Medicine</i> , 2019, 8, 874.	1.0	27
15	Long-term follow-up of papillary and follicular thyroid carcinomas with bone metastasis. <i>PLoS ONE</i> , 2017, 12, e0173354.	1.1	23
16	Therapeutic outcome and prognosis in young patients with papillary and follicular thyroid cancer. <i>Pediatric Surgery International</i> , 2012, 28, 489-494.	0.6	16
17	Activity of roniciclib in medullary thyroid cancer. <i>Oncotarget</i> , 2018, 9, 28030-28041.	0.8	16
18	Maternal and fetal outcomes of pregnant women with type 1 diabetes, a national population study. <i>Oncotarget</i> , 2017, 8, 80679-80687.	0.8	15

#	ARTICLE	IF	CITATIONS
19	Epithelialâ€“Mesenchymal Transition Enhances Response to Oncolytic Herpesviral Therapy Through Nectin-1. <i>Human Gene Therapy</i> , 2014, 25, 539-551.	1.4	14
20	The efficacy of radioactive iodine for the treatment of well-differentiated thyroid cancer with distant metastasis. <i>Nuclear Medicine Communications</i> , 2018, 39, 1091-1096.	0.5	14
21	Sensitivity of Squamous Cell Carcinoma Lymph Node Metastases to Herpes Oncolytic Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 1897-1904.	3.2	12
22	Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, 853-864.	1.6	9
23	Familial Aggregation and Heritability of Nonmedullary Thyroid Cancer in an Asian Population: A Nationwide Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2521-e2530.	1.8	8
24	Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, 727-738.	1.6	8
25	Effects of roniciclib in preclinical models of anaplastic thyroid cancer. <i>Oncotarget</i> , 2017, 8, 67990-68000.	0.8	8
26	Primary lung cancer with radioiodine avidity: A thyroid cancer cohort study. <i>World Journal of Clinical Cases</i> , 2021, 9, 71-80.	0.3	4
27	Efficacy of adavosertib therapy against anaplastic thyroid cancer. <i>Endocrine-Related Cancer</i> , 2021, 28, 311-324.	1.6	4
28	Therapeutic inhibition of poloâ€“like kinases in anaplastic thyroid cancer. <i>Cancer Science</i> , 2021, 112, 803-814.	1.7	4
29	Survival and Death Causes in Thyroid Cancer in Taiwan: A Nationwide Caseâ€“Control Cohort Study. <i>Cancers</i> , 2021, 13, 3955.	1.7	3
30	Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer. <i>Cancers</i> , 2021, 13, 3487.	1.7	2
31	Therapeutic Outcomes of Recurrent Well-Differentiated Thyroid Carcinomas. <i>International Surgery</i> , 2019, 104, 304-313.	0.0	0